-
The endothelin receptor antagonist bosentan has been shown to improve exercise tolerance, hemodynamics, and clinical deterioration in trials of patients with advanced symptoms due to pulmonary hypertension (WHO functional class III and IV).
-
Following successful reperfusion for acute myocardial infarction (MI) with primary percutaneous coronary intervention (PCI), the persistence of impaired perfusion portends a poor prognosis.
-
It has long been believed, with considerable substantiation, that women have poorer results of percutaneous interventions (PCI) than men, with higher morbidity and mortality rates.
-
The atrial fibrillation and congestive heart Failure (AF-CHF) trial was designed to test the hypothesis that a treatment strategy that involved rhythm control would be superior to rate control in patients with heart failure and left ventricular systolic dysfunction.
-
Patients with diabetes mellitus make up a substantial proportion of those undergoing percutaneous coronary intervention (PCI), and they are at higher risk for post-procedural complications.
-
Although multivessel stenting is an off-label use DES, anecdotal evidence has suggested excellent short-term outcomes, comparable to those achieved with CABG.
-
Haissaguerre and his colleagues from twenty-two world-wide arrhythmia referral centers collected 206 patients with idiopathic ventricular fibrillation.
-
Elevated troponin I is a nonspecific finding, but suggests a poor prognosis regardless of its cause. These investigators from Israel sought to clarify these observations.
-
Shingles vaccine added to CDC list of vaccines for adults 60 and older; CDC recommends Tdap for postpartum women; new study suggests sequential therapy with antibiotics for H. pylori may be more effective than standard therapy; FDA Actions.
-